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Abstract 
The cognitive and behavioral deficits caused by traumatic brain injury (TBI) to the 
immature brain are more severe and persistent than injuries to the adult brain. 
Understanding this developmental sensitivity is critical as children under four years 
age of sustain TBI more frequently than any other age group. One of the first events 
following TBI is the infiltration and degranulation of mast cells in the brain, releasing 
a range of immunomodulatory substances, and inhibition of these cells is 
neuroprotective in other types of neonatal brain injury. We investigated for the first 
time the role of mast cells in mediating injury in a P7 mouse model of pediatric 
contusion-induced TBI. We show that various neural cell types express histamine 
receptors, and histamine exacerbates excitotoxic cell death in primary cultured 
neurons. Cromoglycate, an inhibitor of mast cell degranulation, altered the 
inflammatory phenotype of microglia activated by TBI, reversing several change, but 
accentuating others, when administered before TBI. However, regardless of the time 
of cromoglycate administration, inhibiting mast cell degranulation did not affect cell 
loss, as evaluated by ventricular dilatation or cleaved caspase-3 labeling, or the 
density of activated microglia, neurons or myelin. In double-heterozygous cKit 
mutant mice lacking mast cells, this overall lack of effect was confirmed. Our results 
suggest that the role of mast cells in this model of pediatric TBI is restricted to subtle 
effects but that they are unlikely to be viable neurotherapeutic targets. 
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Significance statement 
Traumatic brain injury is a leading cause of acquired disability and death in infants 
and children. We assessed mast cell (MC) stabilization as a therapeutic strategy in a 
model of pediatric TBI using the immature mouse. MCs infiltrated the brain post-TBI, 
neurons and glia expressed receptors for a histamine (an important factor released 
from MCs), and histamine aggravated neuronal excitotoxic death in vitro. However, 
manipulations of MCs in vivo with pharmacologic or genetically approaches revealed 
that MCs have marginal effects on TBI neuropathology. This suggests that the 
actions of MCs may be of less importance in the immature brain compared to the 
mature brain.  
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Introduction 
Children under the age of four years sustain traumatic brain injury (TBI) more 
frequently than any other age group (Koepsell et al. 2011), and in children under 
two, rates of TBI serious enough to be fatal or to require intensive care support are 
as high as 50 per 100,000 (Keenan et al. 2003). This is of particular concern as the 
cognitive and behavioral deficits caused by TBI to the immature brain are more 
severe and persistent than those observed following comparable injuries to the 
mature (adult) brain (Anderson et al. 2005; Rivara et al. 2012), despite the superior 
potential for repair of the former (Bennet et al. 2013).  This is likely due to the 
combined effect of disrupted normal development and the direct effects of injury. TBI 
in the pediatric population is caused by a diverse range of injuries and insults. These 
include acceleration/deceleration injuries (shaken baby syndrome) as well as 
contusion injuries (direct impact to the skull such as car accidents or falls), both 
inflicted and accidental (Pinto et al. 2012) .  
The primary injury process in TBI is mechanical damage (i.e. shear forces inducing 
vascular damage and bleeding), followed by secondary pathological processes 
including excitotoxicity, ischemia and neuroinflammation (Hagberg et al. 2012; Xiong 
et al. 2013), which lead to mitochondrial dysfunction and cell death. Among the first 
events of the injury response, in both the adult and the developing brain, is the 
degranulation of mast cells (Stokely and Orr 2008), whereby these long-lived and 
self-replicating effectors of the immune system (Dropp 1979; Galli et al. 2005) 
release numerous inflammatory mediators such as histamine, cytokines, lipid 
metabolites and nitric oxide (Silver et al. 1996). Mast cells enter the brain in the early 
postnatal period as part of normal development (Panula et al. 2014). Mast cell 
degranulation is toxic to neurons and glia in vitro and in vivo (Dean et al. 2010; 
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Hendrix et al. 2013), while their stabilization has been shown to have be 
neuroprotective in animal models of neonatal excitotoxicity (Patkai et al. 2001) and 
hypoxia-ischemia (Jin et al. 2007), as well as in adult TBI (Hendrix et al. 2013) and 
stroke (Strbian et al. 2006). However, little is known regarding the involvement of 
mast cells in the injury process triggered by TBI in the developing brain. 
In the current article, we studied the role of mast cells in pediatric TBI using animal 
and cellular models. In rodents, during the first 30 days of life, injury to the brain is 
maximal when TBI occurs on postnatal day (P) 7 (Bittigau et al. 1999). The first three 
postnatal weeks also coincide with the infantile period in humans, characterized by 
several crucial developmental processes (e.g. maximal brain growth, 
synaptogenesis and myelination), in addition to a heightened sensitivity to 
excitotoxicity (Bittigau et al. 1999). We first examined whether neural cells in the 
brain of P7 mice could respond to histamine, the primary molecule released by mast 
cell degranulation, to determine whether this could be a valid injury mechanism. 
Next, we examined the effects of cromoglycate, an inhibitor of mast cell 
degranulation, administered at different time-points relative to TBI, on tissue loss, 
neuroinflammation and the loss of myelin. Finally, we confirmed our observations in 
genetically modified mice deficient in cKit, also known as mast cell growth factor 
receptor or CD117, a receptor tyrosine kinase essential for the differentiation of mast 
cells. 
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Materials and Methods 
Experimental protocols were approved by the Bichat and Robert Debré Hospital 
ethics committee (N°2011-14/676-0050). Protocols were as previously described 
(Chhor et al. 2013; Favrais et al. 2011; Husson et al. 2005; Patkai et al. 2001) and 
adhered to European Union Guidelines for the Care and Use of Animals. In vivo 
procedures were typically carried out between 10am and 1pm (light phase 7am-7pm 
daily); all animals were monitored daily during experimentation. Each experimental 
unit corresponds to a single animal, with groups spread between and across litters. 
Animals were housed (Plexiglas cages 30x18x15cm) together with littermates and 
their dam for the entire experiment, with wood-chip bedding and shredded paper for 
nesting (Pharmaserv, France). Animals had access to standard chow and water ad 
libitum. 
Primary microglial, astrocytic and neuronal cultures  
Microglia: Primary mixed glial cultures were prepared from the cortices of wild-type 
OF1 mice (Charles River, L’Arbresle, France) on post-natal days (P) 0-1 as 
previously described (Chhor et al. 2013; Kaindl et al. 2007). An entire litter was used 
for a culture (for all cell types), and an approximately equal number of males and 
females were identified. In brief, the cortices were dissected after removal of the 
meninges, and mechanically dissociated before resuspension and plating in low-
glucose DMEM (31885, Gibco, Cergy Pontoise, France) supplemented with 10% 
FBS (Gibco) and 0.01% penicillin-streptomycin (Gibco). Microglia were isolated from 
the primary mixed glial cultures by shaking on day in vitro (DIV) 14 and resuspended 
at a concentration of 4x105 cells/ml in 6-well culture plates. Culture purity was 
verified by immunolabeling (n=5 wells) using cell-type-specific antibodies to 
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microglia, astrocytes and neurons as previously described (Chhor et al. 2013) and 
revealed >99% purity for microglia.  
Astrocytes: On DIV14, after shaking off microglia from the primary mixed glial 
cultures above, the microglial cell medium was removed, the plates were treated for 
5 minutes with 0.25% trypsin (Gibco, France), and the remaining cells (astrocytes) 
resuspended in Dulbecco’s modified Eagle’s minimum essential medium 
supplemented with 10% fetal calf serum (Gibco, France) with 0.01% of penicillin-
streptomycin, at a concentration of 6x105 cells/ml and plated in 6-well culture plates. 
Neurons: Primary neuronal cultures were derived from the cerebral cortex of 
embryonic day (E) 14.5 C57Bl/6 mice as previously described (Chhor et al. 2013). In 
brief, after dissection of the cortices and removal of the meninges, the cortices were 
minced, chemically dissociated with 0.0125% trypsin (Gibco) and cells seeded in 96-
well culture plates pre-coated with poly-DL-ornithine (Sigma) and laminin 2.5 µg.ml-1 
(Sigma) at a density of 5 x 104 cells and a final volume of 100µl per well. Cells were 
cultured in Neurobasal Medium (Invitrogen, Illkirch, France) supplemented with 2% 
B27 (Invitrogen), 300µM glutamine (Sigma) and 1% Streptomycin/amphotericin B 
100X (Invitrogen). Half the culture medium was replaced by fresh medium three 
times a week and 5µM arabinocytidine hydrochloride (Sigma) added on DIV3 to kill 
dividing progenitors.  
Primary cultured microglia, astrocytes and neurons were harvested and RNA 
extracted for gene expression analysis, as described below. 
RNA extraction and quantification of gene expression by real-time qPCR 
Preparation of microglia qRT-PCR, primer design, and PCR protocol were similar to 
that previously described (Chhor et al. 2013; Husson et al. 2005; Schang et al. 
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2014). Primer sequences are given in Table I. Gapdh for microglia and neurons and 
Rpl13 for astrocytes were used to standardize gene expression levels in quantitative 
experiments based on prior reference gene suitability testing. The relative quantities 
are expressed as the ratio between the gene of interest and the reference gene. For 
characterization of CD11b-positive cells ex vivo (see below), genes were grouped 
into cytotoxic (CytoT), reparatory/regenerative R-Regen) and immunomodulatory 
(ImmunoM) types, based on standard classification the literature (Colton and Wilcock 
2010; Ransohoff and Perry 2009) and previous work from our group (Chhor et al. 
2013). Analyses were performed with Bio-Rad CFX manager 2.1 software 
(RRID:SCR_003375). 
MTT mitochondrial activity (cell viability) assays 
Primary cultured neurons (DIV11) prepared as above were subjected to a 1-hour 
treatment with 50µM NMDA followed by a 24-hour treatment with different 
concentrations of histamine (1, 10, 100µM; Sigma). They were then subjected to the 
MTT assay, where the bioreduction of MTT, a yellow tetrazolium salt, to formazan by 
mitochondrial enzymes reflects the proportion of living cells. In brief, MTT solution 
(Sigma) was added to a final concentration of 0.85mg/ml to each well of a 96-well 
plate for 1 hour. Medium was then replaced by DMSO (50μl/well). The absorbance 
of formazan was measured at 560nm and 750nm using the Glomax-Multi detection 
system (Promega, Southampton, UK). Data were normalized to the vehicle group. 
Traumatic brain injury model and experimental procedure 
In a TBI model described previously (Kaindl et al. 2007), 7-day-old (P7; weight 4-5g) 
wild-type OF1 mice of both sexes (Charles River, L’Arbresle, France) were randomly 
(alternating animals) allocated to TBI, sham control or TBI+ treatment (PBS or drug) 
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groups. Injury profiles were not different between males and females and data was 
pooled. In a separate experimental work-space within the animal facility, mice were 
anesthetized with isoflurane (8% induction) and subjected to a closed head weight–
drop head trauma, in a process that took no longer than 3 minutes in total. In brief, 
the head was fixed to a stereotaxic frame, the skull surface exposed with a skin 
incision and the contusion device oriented perpendicular to the parietal bone with the 
center of the foot-plate (2mm diameter) positioned 2 mm anterior and 1 mm lateral to 
lambda on the parietal bone. The foot-plate was first allowed to touch the skull and 
was then further depressed by 0.5 mm. The contusion device consisted of a hollow 
stainless-steel cylinder 20 cm in length, perforated at 1 cm intervals to prevent air 
compression, and guiding a 10 g weight falling from a height of 10 cm onto the foot-
plate. The contusion was delivered unilaterally to the left side of the skull by the 
same operator for all animals in a given experiment, and cortical contusions were of 
comparable severity in all animals. Body temperature was kept constant via the use 
of a heating pad maintained at 37 °C until pups were returned to their dams, 
approximately 15 minutes post-TBI. A single intraperitoneal injection of cromoglycate 
(50mg/kg in PBS; Sigma) or PBS was administered 1 hour before or 1 hour after TBI 
(Fig. 1). All tissue processing and analyses were carried out by investigators blind to 
the treatment group. 
cKit mice 
Double-heterozygous cKitWv/W mice on a C57Bl/6 background (Jackson Laboratory; 
RRID: IMSR_JAX:000049) as used previously in our lab (Patkai et al. 2001), were 
subjected to TBI experiments following the protocol described above. In this colony, 
the homozygous condition is lethal, heterozygotes for both alleles are white in color 
and lack mast cells, heterozygotes for either allele alone have various degrees of 
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white spotting and functional mast cells, and wild-type mice are black (Meininger et 
al. 1992). In order to limit variability between mutant animals and controls, we chose 
single-heterozygous mice (cKitWv/+ or cKitW/+) as controls for mast-cell deficient 
double-heterozygotes once initial comparisons between cKitWv/+ and cKitW/+ mice and 
between single-heterozygous mice and wild-type mice revealed no significant 
differences among experimental parameters. Phenotype-genotype correlations were 
confirmed before experimentation by PCR and restriction enzyme digestion (Nsi1), 
and revealed a 100% match. 
Tissue preparation and histology 
Assessment of mast cell numbers: Four hours after TBI, mice were transcardially 
perfused with 4% paraformaldehyde–0.12M PBS, the scalp was removed and the 
head with the skull post-fixed in 4% formol overnight (to preserve the meninges) 
before immersion in a 5% nitric acid bath for 1 hour to decalcify the skull. Brains 
were then post-fixed in 4% formol for an additional 4 days before embedding in 
paraffin, 16µm coronal sections cut and collected on Superfrost Plus slides, and 
stained with 1% Toluidine Blue (Fisher Scientific, Leicestershire, UK), which labels 
mast cell granules rich in heparin and histamine, as previously described (Patkai et 
al. 2001). The number of mast cells in the brain and meninges was calculated from 
counts under a 10X objective on a Leica DM6000 B microscope (Leica Microsystems 
Ltd.; RRID:SCR_000011) in two entire sections from the area of maximum lesioning, 
at approximately bregma -1.50mm and -3.50mm. Data shown are average counts 
per section (both hemispheres) for each treatment group. 
Nissl staining and immunohistochemistry: One or five days after TBI, animals were 
sacrificed by decapitation, brains were immersion fixed (4%formol for 5 days), 
embedded in paraffin and 16µm coronal sections cut from the frontal pole to the 
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occipital lobes. One series of sections was stained with cresyl violet for the 
determination of ventricular area as described previously (Kaindl et al. 2007). In 
short, the border of each lateral ventricle from three sections at 192µm intervals 
spanning the hippocampus and mid-striatum was outlined, the cross-sectional 
ventricular areas determined using ImageJ software (version 1.43; NIH, Bethesda, 
MD, USA; RRID:SCR_003070), and the ratio between ventricular areas in the 
traumatized (ipsilateral; left) and non-traumatized hemispheres (contralateral; right) 
determined as previously described (Kaindl et al. 2012; Turner et al. 2003). No 
differences were noted in ventricular areas between the contralateral hemispheres of 
sham and TBI mice. Immunohistochemistry (IHC) was performed as previously 
described (Fleiss et al. 2012), using the following antibodies (see Table II): rabbit 
monoclonal anti-Iba1 (1:1000, Wako Chemicals USA), rabbit monoclonal anti-
CCasp3 (1:200, Cell Signalling), mouse monoclonal anti-MBP (1:500, Millipore), 
mouse monoclonal anti-MAP2 (1:2000, Sigma). After overnight incubation with 
primary antibodies and washing, sections were incubated with appropriate 
fluorescent secondary antibodies (Vectorlabs, California, USA) at 1:200. The number 
of immunolabeled cells or area of immunolabeling was assessed as previously 
described (Fleiss et al. 2012). Briefly, for Iba1 and CCasp3 immunolabeling, two 
images were captured at the level of maximum lesion (approximately -1.50mm) with 
a Leica DM6000 B microscope (Leica Microsystems Ltd.; RRID: SCR_000011) using 
a 10X objective. Counts were made of the number of labeled cells in the parietal 
cortex and striatum of each hemisphere using ImageJ software, and cell numbers 
within a given region expressed as cells/mm2. For MAP2 and MBP, labeling was 
measured in 4-6 levels per brain (one 16μm-thick section every 576 μm) as 
previously described (Fleiss et al. 2012). Volumes of MAP2 and MBP-positive brain 
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tissue were calculated from area measurements according to Cavalieri’s principle 
using the following formula: V = SA × P × T, where V is the total volume, SA is the 
sum of the areas measured, P is the inverse of the sampling fraction and T is section 
thickness. The difference between the two hemispheres was expressed as the ratio 
between values for the ipsilateral and contralateral hemispheres. 
Isolation of CD11b-positive cells using magnetic bead-coupled antibodies 
(MACS) 
At 24 hours and 5-days following TBI, CD11b-positive cells were extracted from the 
whole cortex of unfixed brains using a magnetic bead-coupled antibody system 
(MACS: Miltenyi Biotec, Bergisch Gladbach, Germany; RRID: AB_244268). In brief, 
the olfactory bulbs and cerebellum were removed, and for each data point, 3-4 
hemispheres were pooled (for sufficient RNA yields) and mechanically and 
enzymatically digested using the Neural Tissue Dissociation Kit (Miltenyi Biotec). 
Homogenized and digested tissue was incubated with PE-conjugated anti-CD11b 
antibodies, and CD11b+ cells were separated in a magnetic field before being 
counted and frozen at -80°C. The purity of the separation was assessed using qRT-
PCR for GFAP (astrocytes), MBP (oligodendrocytes), NeuN (neurons) and CD11b 
(microglia) and showed levels of contamination of less than 5%. 
 
Statistics 
Data are from three or more independent experiments and are presented as means 
± SEM. No animals were excluded from the analysis. The appropriate statistical 
tests were chosen based on data normality (Kolmogorov-Smirnov test). A one-way 
Anova was used to compare qRT-PCR results. Mann-Whitney U tests or Kruskall-
Wallis tests followed by Dunnett's post hoc test were used for all other experiments. 
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The statistical test (performed with GraphPad 5.0 software [San Diego, CA, USA], 
RRID: SCR_002798) performed on each data set is indicated in the figure legend or 
within the text and statistically significant results (threshold set at p≤0.05) indicated 
by asterisks.  
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Results  
Histamine receptors are present on neural cells, and histamine aggravates 
excitotoxic neuronal death 
As a first step in determining any role of mast cell degranulation in TBI, we asked 
whether various neural cell types could respond to histamine, one of the principal 
immunomodulatory substances released by mast cells. Quantitative RT-PCR for 
histamine receptors 1-4 revealed the expression of several receptors, with the 
particular abundance of the histamine H2 receptor (H2R), in primary cultures of 
neurons, microglia and astrocytes (Fig. 2A-C) (n=3). We next asked whether 
histamine could affect neuronal death due to excitotoxicity, one of the major injury 
mechanisms involved in TBI, by treating primary neuronal cultures (DIV11) with the 
glutamate agonist N-methyl D-aspartate (NMDA). MTT assays for cell viability 
revealed that NMDA-mediated neuronal death was aggravated in a dose-dependent 
manner by histamine (Fig. 2D) (One way ANOVA; F (3;76) = 25.27, n=16-24 
wells/group (n=5-6 independent cultures); NMDA vs. NMDA + histamine 1μl: non-
significant; NMDA vs. NMDA + histamine 10μl, p <0.001; NMDA vs. histamine 100μl, 
p <0.001; in Kruskall-Wallis post-test). Histamine added to healthy neuronal cultures 
did not significantly affect their viability (data not shown). Together, these data 
suggest that histamine released by mast cell degranulation could indeed play a role 
in the pathogenesis of TBI, either by directly modulating excitotoxic neuronal death 
or by acting through glial cells such as microglia or astrocytes, activated as part of 
the injury response.  
Cromoglycate administration before TBI prevents mast cell degranulation and 
modifies neuroinflammatory processes 
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Next we assessed whether an inhibitor of mast cell degranulation, cromoglycate, 
could enter the brain and prevent the deleterious consequences of TBI. In OF1 pups 
at P7, TBI induced a significant increase in the number of Toluidine-Blue-stained 
mast cells in the brain (cortex, striatum, thalamus) and meninges 4h after injury 
when compared to sham-operated pups, suggesting an influx of circulating mast 
cells (Fig. 3A,B) (Sham vs. TBI, 2.1±0.4 vs. 8.8±1.9 in the brain parenchyma 
(U=19.5, n=7, p=0.0009) and 5.4±0.8 vs. 10.3±1.6 in the meninges (U=35.5, n=7, 
p=0.01), respectively; Mann-Whitney U test). Cromoglycate 50mg/kg administered 
intraperitoneally 1h before TBI further increased the number of Toluidine-Blue-
positive mast cells in the meninges (Fig. 3C,D) (U=27, n=12; p=0.004; Mann-
Whitney U test), with a similar but non-significant increase in the brain. 
Since one of the mechanisms triggered by TBI is microglial activation and 
neuroinflammation, we then used quantitative RT-PCR at 24h to evaluate the 
expression of a previously validated panel of microglial phenotype markers (Chhor et 
al. 2013) (broadly divided for ease of analysis into CytoT (cytotoxic), R-Regen 
(reparatory/regenerative) or ImmunoM (immunomodulatory) types), as well as 
cytokines/chemokines on MACS-sorted CD11b-positive cells (verified to be >95% 
pure for microglia) to assess the effect of cromoglycate on microglial activation (Fig. 
4). Cromoglycate significantly reversed the TBI-induced increase in two markers of 
cytotoxic phenotype activation in microglia, iNOS (F(9;3.50), n=5-6, p=0.007) and 
Cox-2 (F(9;2.47), n=5-6, p=0.04), and the TBI-induced decrease of two others, 
CD32 (F(9;5.90), n=5-6, p=0.0002) and CD86 (F(9;2.36), n=5-6, p=0.04) (Fig. 4A, 
top panel) (n=5-6; one-way Anova with Dunnett's post hoc test). Whereas no 
reparatory/regenerative phenotype markers studied were affected (Fig. 4A, middle 
panel), cromoglycate further reduced two immunomodulatory phenotype markers 
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whose expression was reduced by TBI – SOCS3 (F(9;2.67), n=5-6, p=0.03) and IL-
4Rα (F(9;2.23), n=5-6, p=0.05) (Fig. 4A; bottom panel) (n=5-6; one-way Anova with 
Dunnett's post hoc test). Among the cytokines/chemokines assayed, cromoglycate 
significantly reduced levels of the pro-inflammatory cytokine TNFα (F(9;2.20), n=5-6, 
p=0.05), (reversing its TBI-induced increase), and reduced levels of the chemokine 
CCL3 (or MIP1α; F(9;3.22), n=5-6, p=0.01), in addition to further reducing levels of 
the anti-inflammatory cytokine IL-10 (Fig. 4B) (F(9; 2.84), n=5-6, p=0.02; All analysis 
via one-way Anova with Dunnett's post hoc test). To summarize, cromoglycate 
administration before TBI did indeed inhibit TBI-induced mast cell degranulation as 
well as altering the inflammatory status of activated microglia. 
Cromoglycate administration after TBI does not prevent tissue loss or 
neuropathological changes at the cellular level. 
Since any neuroprotective molecule destined for therapeutic application needs to be 
effective when administered after injury, we assessed the effects of cromoglycate 
given 1h after TBI. As an index of tissue loss following TBI, ventricular dilatation was 
assessed + 1 day and + 5 days after TBI (i.e. on P8 and P12) by calculating the size 
of the ventricle in the lesioned ipsilateral hemisphere as a percentage of the size of 
the ventricle of the contralateral hemisphere in cresyl-violet-stained sections (Fig. 
5A,B). TBI induced an increase in ventricular volume on the ipsilateral side 
compared to the contralateral side at + 5 days post-TBI. However, cromoglycate 
treatment did not significantly alter ventricular volumes at + 1 day (U=3, n=4-6; 
p=0.07) or 5 days (Fig. 5C,D) (n=9-10; p=0.56; Mann-Whitney U test). TBI also 
induced significant cellular labeling for cleaved caspase-3 (CCasp3) on + 1 day in 
the cortex and striatum underlying the contusion site (Fig. 5E,F) (U=0, n=4-6; 
p=0.002 for both regions; Mann-Whitney U test), as well as other brain regions 
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(thalamic nuclei, hippocampal dentate gyrus and subiculum; not shown). In 
agreement with ventricular volumes, however, cromoglycate did not significantly 
reduce CCasp3 density on the ipsilateral side (Fig. 5E,F) (n=4-6; p=0.17, cortex; 
p=1.0, striatum; Mann-Whitney U test; differences were also non-significant for the 
contralateral side). Sham groups not subjected to TBI and treated with vehicle 
and/or cromoglycate displayed no change in ventricular size and had very low 
numbers of CCasp3-positive cells (data not shown). 
Next, we asked whether the changes in neuroinflammation-related molecules 
observed following cromoglycate treatment in MACS-sorted microglia were reflected 
in the number of microglia, or subsequent neuronal death and myelination deficits. 
The density of Iba1-positive microglia observed by immunohistochemistry on + 1 day 
following TBI (i.e. P8) was slightly increased in the cortex and striatum of the 
ipsilateral side when compared to the contralateral side in PBS-treated TBI animals 
(U=1, n=5; p=0.02, cortex; p=0.05, striatum; Mann-Whitney U test). However, 
cromoglycate treatment did not significantly modify microglial numbers (Fig. 6A,B) 
(n=4; p=0.33, cortex; p=0.41, striatum; Mann-Whitney U test). Furthermore, on + 5 
days after TBI (i.e. P12), there was no observable effect of cromoglycate on the area 
of immunolabeling for the neuronal marker MAP2 (p=0.72) or the myelin marker 
MBP (myelin basic protein; p=0.08) on the ipsilateral side compared to the 
contralateral side (Fig. 6C,D) (n=9-10; Mann-Whitney U test). The density of Iba1-
positive microglia and GFAP-positive astrocytes was also quantified on + 5 days, 
and revealed no change with cromoglycate treatment (data not shown). Altogether 
these data indicate that inhibiting mast cell degranulation 1h after TBI did not protect 
against inflammatory microglial activation, neuronal death or myelination damage.  
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Cromoglycate administration before TBI does not prevent ventricular 
dilatation or apoptosis 
We noted above a discrepancy between the effects of cromoglycate on the 
activation of microglia (observed in ex vivo MACS-sorted CD11b-positive cells) and 
the lack of a significant effect on cellular apoptosis and tissue loss in vivo. As such, 
we asked whether mast cell degranulation, which is an extremely rapid event, might 
exert greater effects at a very early post-injury stage, necessitating cromoglycate 
treatment before TBI for any improvement in neuropathology to be observable. We 
therefore repeated the experiment above but with cromoglycate administration 1h 
before TBI, and measured changes in ventricular volume on + 1 day and + 5 days 
and CCasp3-positive cells on + 1 day. While these results were still not significant, 
cromoglycate administered before TBI, did appear to increase tissue loss as 
measured by ventricular dilatation on + 5 days, but not at + 1 day (Fig. 7A,B) (n=7-
10, p=0.27 for + 1 day; n=5-6, p=0.66 for + 5 days; Mann-Whitney U test). The 
density of apoptotic CCasp3-positive cells in the cortex or striatum of pups on + 1 
day was also unchanged on the ipsilateral side (Fig. 7C,D) (n=7-10; p=0.47, cortex; 
p=0.70, striatum; Mann-Whitney U test; differences were also non-significant for the 
contralateral side). Altogether these data indicate that blocking mast cell 
degranulation before TBI was insufficient to affect TBI outcome. 
Mast-cell-deficient mice do not display altered neuropathological changes 
following TBI 
Finally, we aimed to verify that it was not a dose- or treatment-regimen-specific 
effect that led us to see no effect of targeting mast cells using cromoglycate in our 
pediatric TBI model. As such, we used double-heterozygous mice (cKitWv/W) lacking 
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functional cKit leading to mast cell depletion, with single-heterozygous littermates as 
controls. cKitWv/W mice subjected to TBI at P7 and sacrificed 1 day later showed no 
difference in the TBI-induced increase in ventricular volume when compared to 
single-heterozygous mice (cKitWv/+ or cKitW/+) (Fig. 8A) (n=9-13; p=0.23; Mann-
Whitney U test), but did show a significant increase in ventricular volume when 
sacrificed at + 5 days (Fig. 8B) (U=11, n=7-10; p=0.02; Mann-Whitney U test). The 
density of CCasp3-positive cells was not significantly different between the cortex 
and striatum of cKitWv/W mice and single-heterozygous controls on + 1 day (Fig. 
8C,D) (n=9-13; p=0.14, cortex; p=0.36, striatum; Mann-Whitney U test).  
In addition, cKitWv/W mice were also not significantly different from their single-
heterozygous littermates in terms of the density of Iba1-positive microglia in the 
cortex or striatum at + 1 day (Fig. 9A,B) (n=9-13; p=0.42 for the cortex; p=0.76 for 
the striatum; Mann-Whitney U test). Similarly, on + 5 days, both groups of mice had 
a similar area measurements of MAP2 immunolabeling as a proxy of neuronal 
number (Fig. 9C) (n=7-10; p=0.47; Mann-Whitney U test) and MBP immunolabeling 
as a measure of myelination (Fig. 9D) (n=7-10; p=0.89; Mann-Whitney U test). To 
summarize, the absence of mast cells, while increasing ventricular dilatation at the 
late but not early time point assessed, did not significantly influence cell death, 
microglial number or surrogates of myelination or healthy mature neurons following 
TBI. 
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Discussion  
Previous observations indicate that mast cells infiltrate the brain and degranulate 
following adult TBI (Levy et al. 2015; Lozada et al. 2005), which triggers neuronal 
death, reactive gliosis, blood brain barrier opening, and myelination deficits in the 
brain through inflammatory and excitotoxic pathways (Stokely and Orr 2008). As 
such, we examined the possibility that mast-cell-released molecules could influence 
the injury mechanisms involved in a model of pediatric TBI. Our results show that 
several neural cell types express receptors for histamine, one of the main molecules 
released by mast cells and a mediator of inflammation, and that histamine 
exacerbates excitotoxic cell death in primary neuronal cultures. Furthermore, 
cromoglycate, an inhibitor of mast cell degranulation, when administered peripherally 
before TBI increased the numbers of toluidine blue positive mast cells (as previously 
reported in rats (Dong et al. 2016; Strbian et al. 2007)). This suggests that 
cromoglycate effectively inhibited degranulation of the mast cells that infiltrated the 
brain following TBI. However, we did not specifically count the degranulated cells 
due to difficulties in finding these ‘ghost’ cells as after they release their histamine 
granulates these dissipate. As such, we can only make assumptions that increases 
in number reflect decreased degranulation as previously reported (Levy et al. 2015). 
Cromoglycate has limited but significant effects on markers and cytokines typical of 
activation states of microglia, the principal mediators of inflammation in the brain. 
However, regardless of whether cromglycate was administered 1h before or 1h after 
TBI, it did not affect TBI-induced ventricular dilatation, apoptosis, increased 
microglial numbers or measures of neuronal density or myelination. Finally, the lack 
of an effect of stabilizing mast cells using a pharmacological approach on outcome 
in this model of pediatric TBI can be largely reproduced in a transgenic mouse line in 
Moretti et al: Mast cells in pediatric TBI 
 22 
which mice lack functional cKit and as such have no mast cells. It thus appears that 
the influx of mast cells following TBI in the pediatric brain is either not sufficient to 
influence the majority of the neuropathological mechanisms triggered, or has effects 
limited to parameters that were not measured in our experiments.  
 
This is the first study to examine the role of mast cells in a pediatric TBI model. 
However, we have previously identified a role for these cells in a model of 
excitotoxicity in the immature brain (Mesples et al. 2005; Patkai et al. 2001), and 
cromoglycate has been shown to significantly reduce lesion size in a neonatal model 
of hypoxia-ischemia (Jin et al. 2007). We chose a closed-contusion weight-drop 
model of TBI in P7 mice for this study, as the injury mechanisms triggered in this 
model are similar to those seen in pediatric TBI (Xiong et al. 2013). Our observations 
on the distribution and timing of cell death are generally in agreement with previous 
studies using a similar closed-contusion model in neonatal rodents (Bittigau et al. 
1999; Kaindl et al. 2007). In an adult TBI model using the same mast-cell-deficient 
(cKit knockout) mice used in this study (Hendrix et al. 2013), mast cells were found 
to be protective, and associated with reduced lesion size, astrogliosis and T cell 
infiltration. In our pediatric model, however, apart from an indication that TBI-induced 
ventricular dilatation could be aggravated in the absence of mast cells, the cellular 
and myelination markers measured were not affected in cKit mice. There are several 
physiological reasons why the effects of mast cells in TBI might differ between the 
adult and neonatal brain, including i) the substantially greater number of mast cells 
in the brain of neonatal rodents and humans compared with adults (Dropp 1979; 
Khalil et al. 2007), ii) the differential effects of mast cell granular contents on the 
vasculature (Ribatti 2015; Stolp et al. 2005), and iii) the developmental regulation of 
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mast cell phenotype, including the types of chymases produced (Dimitriadou et al. 
1996). Indeed, mast cell granules contain a variety of molecules in addition to 
histamine – heparin, various cytokines as well as several chymases etc. – capable 
of mediating either injury or neuroprotection, and the exact effects of their 
degranulation could depend on both age and the injury context (Hendrix et al. 2013; 
Piliponsky et al. 2012). Further in-depth mechanistic studies are required to 
elucidate the differences in the underlying neuropathology between 
hypoxic/ischemic and excitotoxic injury versus TBI in neonates, and the role of mast 
cells in these differences.  
The specificity of cromoglycate as a stabilizer of mast cells in mice is contested but it 
is acknowledged that even in rats where this drug is considered mast cell specific 
that subpopulations of mast cells respond very differently to cromoglycate exposure 
(Chen et al. 2001). In addition, as mentioned above that there are striking 
differences between neonatal and adult mast cells that may influence specificity and 
effect size (Dimitriadou et al. 1996; Khalil et al. 2007; Monk et al. 2007), and these 
variables have not been addressed in the literature regarding the differences 
between mice and rat responses to cromoglycate. Furthermore, supporting the 
efficacy of cromoglycate in mice is that it has been demonstrated to reduce IgM 
mediated autoimmunity in a mouse model, an effect not observed in cKit mast cell 
KO mice (Chen et al. 2001); in a mouse model of peripheral nerve injury 
cromoglycate prevented mast cell recruitment into the injury (Monk et al. 2007); and 
we noted that treatment increased the number of mast cells, suggesting they were 
prevented from degranulation due to TBI.  Together with the strong safety profile of 
cromoglycate in the pediatric population this previous work using cromoglycate in 
mice justifies the use of this compound in this study. 
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We observed mast cell recruitment primarily in the meninges as previously reported 
in an adult model of TBI (Shimada et al. 2012) although we did not count 
degranulated ‘ghost’ mast cell numbers to directly replicate the observation that in 
addition to recruitment there is degranulation of mast cells, such as after adult TBI 
(Lozada et al. 2005) or neonatal hypoxia-ischemia (Biran et al. 2008; Jin et al. 2009). 
We deduce from the further increase in mast cell numbers from TBI only levels 
caused by cromoglycate that degranulation of these recruited mast cells was 
prevented. However, unlike previous reports, we did not observe an increase in 
microglial number following the inhibition of mast cell degranulation (Hendrix et al. 
2013). Cromoglycate was able to generally reduce the pro-inflammatory associated 
markers in TBI-activated microglia (i.e., reducing iNOS, COX2 and TNFa). However, 
the response of microglia was small overall in response to TBI as compared to 
insults such as lipopolysaccharide exposure (Smith et al. 2014). In contrast to our 
observations an anti-inflammatory effect of histamine on activated microglia has 
previously been reported (Ferreira et al. 2012).  
 
In summary, mast cells infiltrate the brain and degranulate following TBI at P7. 
However, despite some modulatory effects of mast cell degranulation on the 
inflammatory phenotype of microglia, pharmacologically suppressing mast cell 
activity or genetically eliminating mast cells had little effect on tissue loss or 
associated cellular and neuroanatomical changes in our model. This suggests that 
compared to the adult brain, the effects of mast cells in TBI during development may 
be limited and not a viable target as a neurotherapeutic. 
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Table I: Primer sequences and NCBI references 
Gene Sense Anti-sense NCBI Reference 
Gapdh GGC CTT CCG TGT TCC TAC TGT CAT CAT ATC TGG CAG GTT NM_008084.2 
Rpl13 ACA GCC ACT CTG GAG GAG AA 
 
GAG TCC GTT GGT CTT GAG GA 
 
NM_016738.5 
iNos CCC TTC AAT GGT TGG TAC ATG G ACA TTG ATC TCC GTG ACA GCC NM_010927.3 
CD32 CTG GAA GAA GCT GCC AAA AC CCA ATG CCA AGG GAG ACT AA NM_010187.2 
CD86 GAG CGG GAT AGT AAC GCT GA GGC TCT CAC TGC CTT CAC TC NM_019388.3 
Ptgs2 TCA TTC ACC AGA CAG ATT GCT AAG CGT TTG CGG TAC TCA TT NM_011198.3 
CD206 CTT CGG GCC TTT GGA ATA AT TAG AAG AGC CCT TGG GTT GA NM_008625.2 
Arg1 GTG AAG AAC CCA CGG TCT GT GCC AGA GAT GCT TCC AAC TG NM_007482.3 
Lgals3 GAT CAC AAT CAT GGG CAC AG ATT GAA GCG GGG GTT AAA GT NM_010705.3 
Igf1 TGG ATG CTC TTC AGT TCG TG GCA ACA CTC ATC CAC AAT GC NM_010512.4 
Sphk1 TCC AGA AAC CCC TGT GTA GC CAG CAG TGT GCA GTT GAT GA NM_001172475.1 
Il1rn TTG TGC CAA GTC TGG AGA TG TTC TCA GAG CGG ATG AAG GT NM_031167.5 
Il4ra GGA TAA GCA GAC CCG AAG C ACT CTG GAG AGA CTT GGT TGG NM_001008700.3 
Socs3 CGT TGA CAG TCT TCC GAC AA TAT TCT GGG GGC GAG AAG AT NM_007707.3 
IL1b GGG CCT CAA AGG AAA GAA TC TCT TCT TTG GGT ATT GCT TGG NM_008361.3 
IL-6 CAA AGC CAG AGT CCT TCA GA GCC ACT CCT TCT GTG ACT CC NM_031168.1 
IL10 CTC CCC TGT GAA AAT AAG AGC GCC TTG TAG ACA CCT TGG TC NM_010548.2 
IL-12a TCA CAA CCA TCA GCA GAT CA TGC AGA GCT TCA TTT TCA CTC NM_001159424.1 
IL-12b ATC CAG CGC AAG AAA GAA AA AAT AGC GAT CCT GAG CTT GC NM_008352.2 
IL-18 TTC GTT GAC AAA AGA CAG CC TAT CAG TCT GGT CTG GGG TTC NM_008360.1 
Tnfa GCC TCT TCT CAT TCC TGC TT AGG GTC TGG GCC ATA GAA CT NM_013693.3 
Cxcl1 GCA CCC AAA CCG AAG TCA TA AGG TGC CAT CAG AGC AGT CT NM_008176.3 
Cxcl10 GGG TAA AGG GAG GTG GAG AG GCT TAT TGA AAG CGG TGA GC NM_021274.2 
Ccl2 CAT CCA CGT GTT GGC TCA TCA TTG GGA TCA TCT TGC TG NM_011333.3 
Ccl3 TTT TGA AAC CAG CAG CCT TT CTG CCT CCA AGA CTC TCA GG NM_011337.2 
Hrh1 GGG CTC AAA GGC CAA TGA C ACT GTC GAT CCA CCA AGG TC NM_008285.3 
Hrh2 CTG GCT GTC AGC TTG AAT CG CCA AAG CTC CAC TTG AAG GA NM_001010973.2 
Hrh3 CCA TCT CCG ACT TCC TCG T AGT CTA CCA CCA GCC ACA GC NM_133849.3 
Hrh4 GCT ACG ATC GAT ACC AGT CA AAG AAA GCC AGT ATC CAA ACA G NM_153087.2 
Mbp CCG GAC CCA AGA TGA AAA C CTT GGG ATG GAG GTG GTG T NM_010777.3 
Gfap CTC CTG GTA ACT GGC CGA CT AAG CCA AGC ACG AAG CTA AC NM_010277.3 
NeuN CGA TGC TGT AGG TTG CTG TG CAG ATA TGC TCA GCC AGC AG NM_001039168.1 
CD11b CTG GTG CTC TTG GCT CTC AT GGC AGC TTC ATT CAT CAT GT NM_001082960.1 
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Table II. Antibodies used 
Name of antibody Immunogen Manufacturer, catalog 
number, RRID, 
monoclonal/polyclonal 
antibody, species 
Concentration 
Anti Iba-1 (Ionized 
calcium-binding 
adaptor molecule 1) 
Iba1 carboxy-
terminal sequence 
Wako, 019-19741, 
AB_839504, polyclonal 
antibody, Rabbit 
1:1000 
Anti Cleaved 
Caspase-3 
Amino-terminal 
residues adjacent to 
(Asp175) in human 
caspase-3 
Cell signaling, 9661, 
AB_331440, monoclonal 
antibody, Rabbit 
1:200 
Anti-MBP (Myelin 
Basic Protein) 
Amino acids 129-
138 of Myelin Basic 
Protein 
Millipore, MAB382, 
AB_94971, monoclonal 
antibody, Mouse 
1:500 
Anti-MAP2 
(Microtubule-
associated protein-2) 
Rat brain 
microtubule 
associated  
proteins (MAPs) 
Sigma-Aldrich, M4403, 
AB_477193, monoclonal 
antibody, Mouse 
1:2000 
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Figure Legends  
Figure 1. Schematic representation of experimental protocols. Cromoglycate 
was administered either before or after TBI. cKit mice underwent TBI but not 
cromoglycate treatment. CCasp3: cleaved caspase 3; Iba1: ionized calcium-binding 
adaptor molecule 1 (microglial marker); MAP2: microtubule-associated protein 2 
(neuronal marker); MBP: myelin basic protein (marker of myelination/myelinating 
oligodendrocytes); TBI: traumatic brain injury. 
Figure 2. Histamine receptor expression in neural cells and histamine-
mediated potentiation of excitotoxic neuronal death. Expression of histamine 
receptor subunits in primary cultured microglia (A), astrocytes (B) and neurons (C) 
as measured by qRT-PCR. D) Effects of histamine on NMDA-mediated neuronal 
death in vitro. Data expressed as mean±SEM (n=16 wells/group in 3 different 
experiments). ***: p <0.001; one-way ANOVA with Dunnett’s post hoc test, 
compared to NMDA treatment only. 
Figure 3. Induction of mast cell recruitment by TBI and prevention of mast cell 
degranulation by cromoglycate. A) Representative images of Toluidine-Blue-
positive mast cells in the periventricular parenchyma at bregma 1.5, scale bar: 
100μm. B) Quantification of Toluidine-Blue-positive cells in the meninges and total 
brain parenchyma. Data expressed as mean±SEM (n=7 animals/group) and groups 
were compared with a Mann-Whitney U test. *: p<0.05, **: p<0.01. ***: p<0.001. 
Figure 4. Effects of pre-TBI cromoglycate treatment on expression of 
microglial phenotype markers and cytokines/chemokines. Data are shown 
normalized to expression levels in the sham group (dotted line) and expressed as 
mean±SEM (n=5-6 mice per group). Genes are grouped based on predicted role in 
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inflammation: cytotoxic (CytoT), reparatory/regenerative (R-Regen) and 
immunomodulatory (ImmunoM), with PBS-treated groups in white and cromoglycate-
treated (Cromo) groups in shades of grey. Groups were compared using one-way 
Anova with Dunnett's post test. *: p<0.05. **: p<0.01. In MACS-sorted CD11b+ 
microglia at + 1 day post-TBI A) microglial phenotype markers and B) microglial 
cytokine/chemokine gene expression.  
Figure 5. Effects of post-TBI cromoglycate administration on neuropathology. 
A, B) Representative images of cresyl violet stained sections from animals treated 
with PBS (A) or cromoglycate (B) 1h after TBI, indicating ventricular cross-sectional 
area (green: right/contralateral hemisphere; red: left/ipsilateral hemisphere). 
Ventricular dilatation was used as an index of tissue loss. C, D) Quantification of 
ventricular area on + 1 day (C) and + 5 days after TBI (D). E, F) Quantification of 
density of cleaved caspase 3 (CCasp3)-positive cells in PBS- versus cromoglycate-
treated animals in the cortex (E) and striatum (F). Data expressed as mean±SEM 
(n=4-6 for +1 day; n=9-10 for + 5 days); groups were compared using a Mann-
Whitney U test. There were no significant differences other than between ipsilateral 
and contralateral hemispheres (not indicated).  
Figure 6. Effects of post-TBI cromoglycate administration on microglial, 
neuronal and myelin markers. A, B) Quantification of the density of Iba1-positive 
cells on + 1 day and + 5 days in PBS- and cromoglycate-treated (1h after TBI) mice 
within the cortex (A) and striatum (B). C) Quantification of neuronal loss on + 5 days 
in PBS- and cromoglycate-post-treated mice based on the ratio of the area of MAP2 
immunoreactivity between the traumatized (ipsilateral; left) and non-traumatized 
(contralateral; right) hemispheres. D) Quantification of myelin loss on + 5 days, in 
PBS- and cromoglycate-treated mice based on the ratio of the area of MBP 
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immunoreactivity between the traumatized (ipsilateral; left) and non-traumatized 
(contralateral; right) hemispheres. Data expressed as mean±SEM (n=4 per group for 
+ 1 day; n=9-10 per group for + 5 days). Groups were compared using a Mann-
Whitney U test. There were no significant differences other than between ipsilateral 
and contralateral hemispheres (not indicated). 
Figure 7. Effects of pre-TBI cromoglycate administration on neuropathology. 
A, B) Quantification of ventricular area on + 1 day (A) and + 5 days (B) in PBS- and 
cromoglycate-pretreated (1h before TBI) mice. C, D) Quantification of density of 
cleaved caspase 3 (CCasp3)-positive cells in PBS- versus cromoglycate-treated 
animals in the cortex (C) and striatum (D). Data indicate means ± SEM (n=7-10 for + 
1 day; n=5-6 for + 5 days). Groups were compared using a Mann-Whitney U test. 
There were no significant differences other than between ipsilateral and contralateral 
hemispheres (not indicated). 
Figure 8. Effects of genetic deletion of mast cells on TBI-induced 
neuropathology. A, B) Quantification of ventricular area on + 1 day (A) and + 5 
days (B) after TBI. C, D) Quantification of density of cleaved caspase 3 (CCasp3)-
positive cells in mast-cell deficient double-heterozygous mice (cKitWv/W) versus 
single-heterozygous controls (cKitWv/+ or cKitW/+) in the cortex (C) and striatum (D). 
Data indicate means ± SEM (n=9-13 for + 1 day; n=7-10 for + 5 days). Comparisons 
were carried out using a Mann-Whitney U test. *: p=0.02 There were no other 
significant differences, except for differences between ipsilateral and contralateral 
hemispheres (not indicated). 
Figure 9. Effects of genetic deletion of mast cells on post-TBI microglial, 
neuronal and myelin markers. A, B) Quantification of the density of Iba1-positive 
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cells on + 1 day in mast-cell deficient double-heterozygous mice (cKitWv/W) and 
single-heterozygous controls (cKitWv/+ or cKitW/+) within the cortex (A) and striatum 
(B). C) Quantification of neuronal loss on + 5 days in mast-cell deficient double-
heterozygous mice (cKitWv/W) versus single-heterozygous controls (cKitWv/+ or cKitW/+) 
based on the area of MAP2 immunoreactivity between the traumatized (ipsilateral; 
left) and non-traumatized (contralateral; right) hemispheres. D) Quantification of 
myelin loss at + 5 days post-TBI, in mast-cell deficient double-heterozygous mice 
(cKitWv/W) versus single-heterozygous controls (cKitWv/+ or cKitW/+) based on the ratio 
of the area of MBP immunoreactivity between the traumatized (ipsilateral; left) and 
non-traumatized (contralateral; right) hemispheres. Data indicate means ± SEM 
(n=9-13 for + 1 day; n=7-10 for + 5 days). Comparisons were carried out using a 
Mann-Whitney U test. There were no significant differences other than between 
ipsilateral and contralateral hemispheres (not indicated). 
 
 
